It should also be noted that many epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs; e.g. gefitinib, erlotinib), which are key molecules in non-small cell lung cancer treatment [27] [28] [29] [30], are substrates of P-gp. Here, PGP is linked to non-small cell lung carcinoma.